Lilly: Grove Biopharma: $30 Million Series A Secured For Advancing Therapeutic Modality

Grove Biopharma is a private biotechnology company advancing its Bionic Biologics platform, developing therapies targeting previously intractable intracellular disease targets. The company has announced the closing of a $30 million Series A funding round. DCVC Bio led this funding round with participation from Eli Lilly, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments, and others. And they join existing seed supporters, including Portal Innovations, where Grove was incubated. The post Grove Biopharma: $30 Million Series A Secured For Advancing Therapeutic Modality appeared first on Pulse 2.0.